You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: On Target Therapeutics, LLC Topic: 106
DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NIAID
DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: AFASCI INC Topic: NIDA
DESCRIPTION provided by applicant The abuse of illicit drugs such as cocaine marijuana and heroin remains a critical public health concern throughout the country and is associated with staggering economic and social consequences Cocaine remains the most frequently recorded illicit drug in emergency hospital visits and the leading cause of drug related deaths in the United States Since as hi ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ARISAN THERAPEUTICS INC Topic: NIAID
Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENICS, INC. Topic: NIAID
DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: OMVAX INC Topic: R
For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.SBC: Acumen Pharmaceuticals, Inc Topic: NIA
In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Anasys Instruments Corp. Topic: NIGMS
DESCRIPTION provided by applicant The goal of the proposed Phase II STTR research is to develop an imaging system capable of detecting and identifying biomolecules in cells and tissue sections with sub cellular spatial resolution The system combines an atomic force microscope AFM with mass spectrometry MS analysis and utilizes a unique tip enhanced laser ablation TELA method developed in ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PROTERIS BIOTECH, INC. Topic: N
DESCRIPTION provided by applicant Dry eye a group of disorders that affects million people over the age of in the USA today is characterized by inadequate hydration and lubrication of the ocular surface The final common pathway for all types of dry eye is disruption of the ocular surface barrier which can be assessed by quantifying uptake of water soluble dyes applied topically to the ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Nectome Inc. Topic: 101
Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health